Head and Neck Diseases by Alexandros G.Sfakianakis: Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy

Τρίτη 9 Οκτωβρίου 2018

Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy

Condition: Head and Neck Cancer
Interventions: Procedure: Surgical resection of primary tumor; Radiation: Adjuvant radio(-chemo)therapy; Drug: Neoadjuvant Nivolumab; Drug: Adjuvant Nivolumab; Drug: Adjuvant Nivolumab and Ipilimumab
Sponsors: Universitätsklinikum Hamburg-Eppendorf; University Hospital, Essen; Westpfalz-Clinical Center GmbH; Charite University, Berlin, Germany
Recruiting

https://ift.tt/2OcPfwi

Head and Neck Diseases by Alexandros G.Sfakianakis

Αρχειοθήκη ιστολογίου

! # Ola via Alexandros G.Sfakianakis on Inoreader

Η λίστα ιστολογίων μου

Τρίτη 9 Οκτωβρίου 2018

Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy

Δεν υπάρχουν σχόλια:

Δημοσίευση σχολίου

Αρχειοθήκη ιστολογίου